Literature DB >> 7922157

Neuropeptide Y and cardiovascular regulation.

T Pedrazzini1, H R Brunner, B Waeber.   

Abstract

Neuropeptide Y is a vasoactive peptide and is widely distributed throughout the central and peripheral nervous systems. Neuropeptide Y is co-released with noradrenaline by perivascular nerve endings. At high concentrations, it has a direct vasoconstrictor effect. In addition, it enhances the vascular effect of various agonists, including noradrenaline and angiotensin II. Moreover, neuropeptide Y has an inhibitory effect on renin secretion. This peptide may have an important role in cardiovascular regulation.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7922157     DOI： 10.1097/00041552-199301000-00016

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN： 1062-4821            Impact factor:   2.894


  8 in total

1.  Neuropeptide Y genotype, central obesity, and abdominal fat distribution: the POUNDS LOST trial.

Authors:  Xiaochen Lin; Qibin Qi; Yan Zheng; Tao Huang; Mark Lathrop; Diana Zelenika; George A Bray; Frank M Sacks; Liming Liang; Lu Qi
Journal:  Am J Clin Nutr       Date:  2015-07-08       Impact factor: 7.045

2.  Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation.

Authors:  Oliver Dörr; Sebastian Ewen; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Dominik Linz; Mathias Hohl; Christian Troidl; Timm Bauer; Michael Böhm; Christian Hamm; Felix Mahfoud; Holger Nef
Journal:  Clin Res Cardiol       Date:  2015-05-26       Impact factor: 5.460

3.  Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses.

Authors:  Kuixing Zhang; Fangwen Rao; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Brian Vaught; Yuhong Chen; Tiffany A Greenwood; Andrew J Schork; Lei Wang; Manjula Mahata; Mats Stridsberg; Srikrishna Khandrika; Nilima Biswas; Maple M Fung; Jill Waalen; Rita P Middelberg; Andrew C Heath; Grant W Montgomery; Nicholas G Martin; John B Whitfield; Dewleen G Baker; Nicholas J Schork; Caroline M Nievergelt; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2012-09-26       Impact factor: 24.094

4.  Neuropeptide Y reduces the expression of PLCB2, PLCD1 and selected PLC genes in cultured human endothelial cells.

Authors:  V R Lo Vasco; M Leopizzi; C Puggioni; C Della Rocca; R Businaro
Journal:  Mol Cell Biochem       Date:  2014-06-06       Impact factor: 3.396

5.  Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

Authors:  Manish Suneja; Daryl J Murry; John B Stokes; Victoria S Lim
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-19       Impact factor: 4.310

6.  Berberine for Appetite Suppressant and Prevention of Obesity.

Authors:  Hyun-Jung Park; EunYee Jung; Insop Shim
Journal:  Biomed Res Int       Date:  2020-12-12       Impact factor: 3.411

7.  Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis.

Authors:  Svati H Shah; Neil J Freedman; Lisheng Zhang; David R Crosslin; David H Stone; Carol Haynes; Jessica Johnson; Sarah Nelson; Liyong Wang; Jessica J Connelly; Michael Muehlbauer; Geoffrey S Ginsburg; David C Crossman; Christopher J H Jones; Jeffery Vance; Michael H Sketch; Christopher B Granger; Christopher B Newgard; Simon G Gregory; Pascal J Goldschmidt-Clermont; William E Kraus; Elizabeth R Hauser
Journal:  PLoS Genet       Date:  2009-01-02       Impact factor: 5.917

8.  Elevated Neuropeptide Y in Endothelial Dysfunction Promotes Macrophage Infiltration and Smooth Muscle Foam Cell Formation.

Authors:  Bongkun Choi; Min-Kyung Shin; Eun-Young Kim; Ji-Eun Park; Halim Lee; Seong Who Kim; Jae-Kwan Song; Eun-Ju Chang
Journal:  Front Immunol       Date:  2019-07-18       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.